Arcturus Therapeutics Holdings Management
Management criteria checks 3/4
Arcturus Therapeutics Holdings' CEO is Joe Payne, appointed in Mar 2013, has a tenure of 12.75 years. total yearly compensation is $3.70M, comprised of 18.8% salary and 81.2% bonuses, including company stock and options. directly owns 5.21% of the company’s shares, worth $10.55M. The average tenure of the management team and the board of directors is 4 years and 6.9 years respectively.
Key information
Joe Payne
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 18.80% |
| CEO tenure | 12.8yrs |
| CEO ownership | 5.2% |
| Management average tenure | 4yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%
Oct 28
Arcturus Therapeutics: CF Setback Reinforces The Risks Of Its mRNA Therapeutics
Oct 23Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 32% Jump Looks Justified
Aug 29Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?
Jul 31Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking After Shares Rocket 41%
May 04
KOSTAIVE Approval And Upcoming Vaccine Trials Will Open New Markets
European approval of the mRNA COVID-19 vaccine could significantly boost sales through broader market access in 31 countries.Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet
Mar 20Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results
Mar 09Arcturus: Downgrading As mRNA Promise Meets Market Reality
Jan 28Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data
Nov 14Improved Revenues Required Before Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock's 28% Jump Looks Justified
Oct 04Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$67m |
| Jun 30 2025 | n/a | n/a | -US$60m |
| Mar 31 2025 | n/a | n/a | -US$68m |
| Dec 31 2024 | US$4m | US$695k | -US$81m |
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$72m |
| Mar 31 2024 | n/a | n/a | -US$107m |
| Dec 31 2023 | US$5m | US$698k | -US$30m |
| Sep 30 2023 | n/a | n/a | US$99m |
| Jun 30 2023 | n/a | n/a | US$80m |
| Mar 31 2023 | n/a | n/a | US$111m |
| Dec 31 2022 | US$6m | US$630k | US$9m |
| Sep 30 2022 | n/a | n/a | -US$147m |
| Jun 30 2022 | n/a | n/a | -US$165m |
| Mar 31 2022 | n/a | n/a | -US$198m |
| Dec 31 2021 | US$960k | US$600k | -US$204m |
| Sep 30 2021 | n/a | n/a | -US$196m |
| Jun 30 2021 | n/a | n/a | -US$163m |
| Mar 31 2021 | n/a | n/a | -US$119m |
| Dec 31 2020 | US$13m | US$500k | -US$72m |
| Sep 30 2020 | n/a | n/a | -US$52m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$29m |
| Dec 31 2019 | US$1m | US$450k | -US$26m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$3m | US$425k | -US$22m |
Compensation vs Market: Joe's total compensation ($USD3.70M) is above average for companies of similar size in the US market ($USD1.48M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
CEO
Joe Payne (53 yo)
Mr. Joseph E. Payne, also known as Joe, M.Sc. has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. H...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | US$3.70m | 5.21% $ 10.6m | |
| Founder | 12.9yrs | US$1.59m | 1.53% $ 3.1m | |
| CFO & Director | 7.3yrs | US$1.62m | 0.78% $ 1.6m | |
| Chief Legal Officer | 5.3yrs | US$1.49m | 0% $ 0 | |
| Vice President and Head of IR/PR & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 2.3yrs | no data | no data | |
| Chief Business Officer | 7.3yrs | no data | no data | |
| Chief Medical Officer | 2.6yrs | no data | no data | |
| Chief Development Officer | 2.6yrs | no data | no data | |
| Chief Regulatory Officer | 1.9yrs | no data | no data | |
| Controller | 1.8yrs | no data | no data |
Experienced Management: ARCT's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 12.8yrs | US$3.70m | 5.21% $ 10.6m | |
| CFO & Director | 6.3yrs | US$1.62m | 0.78% $ 1.6m | |
| Independent Director | 7.6yrs | US$374.00k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$366.50k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$374.00k | 0% $ 0 | |
| Independent Chairman of the Board | 1.5yrs | US$579.00k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$361.50k | 0% $ 0 | |
| Member of the Vaccine Platform Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 11yrs | no data | no data | |
| Member of Scientific Advisory Board | 10.1yrs | no data | no data | |
| Strategic Clinical Advisor & Member of Scientific Advisory Board | 3.8yrs | US$644.00k | no data | |
| Member of the Vaccine Platform Scientific Advisory Board | 5.4yrs | no data | no data |
Experienced Board: ARCT's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 08:20 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcturus Therapeutics Holdings Inc. is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |